Providers/Grant Support
This activity is supported by an independent medical educational grant from Leo Pharma.
Credits Available
- Physicians—maximum of 1.0 AMA PRA Category 1 Credit™
All other health care professionals completing this course will be issued a statement of participation.
Target Audience
The target audience for this educational series will be dermatology clinicians (MDs, PAs, NPs, and nurses).
Program Overview
Generalized pustular psoriasis (GPP) can look familiar but missing it can have serious consequences. Uncover how IL-36 signaling and immune dysregulation shape disease presentation, progression, and treatment response. You’ll learn to distinguish GPP from other neutrophilic dermatoses using clinical clues, biomarkers, and diagnostic tools. Explore how emerging targeted therapies are changing what’s possible for patients who previously had limited options. Real-world strategies will help you build comprehensive, long-term management plans that go beyond symptom control. If you’ve ever second-guessed a pustular case, this activity will sharpen your clinical instincts.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Analyze the role of IL-36 signaling and other immune pathways in the pathogenesis of GPP and related conditions
- Differentiate GPP from other neutrophilic dermatoses using clinical presentation and immunological markers as well as clinical tools and biomarker-based disease evaluation
- Evaluate the efficacy of current and emerging targeted therapies for GPP based on their immunological mechanisms of action
- Formulate comprehensive management plans for GPP patients that incorporate both dermatological and immunological considerations
Faculty
Anthony Fernandez, MD, PhD
Director of Medical Dermatology
WD Steck Chair of Clinical Dermatology
Cleveland Clinic
Cleveland, OH
Accreditation Statement
This activity is jointly provided by The France Foundation and the American Association of Immunologists.
Credit Designation
The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other health care professionals completing this course will be issued a statement of participation.
Disclosures of Conflict of Interest
Anthony Fernandez, MD, PhD
Planning Committee Chair
1. Consultant-Biogen, Johnson & Johnson, Takeda, Galderma, EMD Serono, Mallinckrodt
2. Speakers bureau-Mallinckrodt, BMS, Galderma, Amgen
3. Contract research-Pfizer, Priovant, AstraZeneca, Boehringer Ingelheim, Castle Biosciences, Incyte
Margaret Das, PhD – Medical Writer, The France Foundation – Planning Committee, Peer Reviewer – No relevant financial disclosures
All final planning decisions concerning content, learning objectives, and evaluation questions were made by a non-conflicted planning committee chair. Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Instructions for Participation and Credit
There are no fees for participating in and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the posttest and evaluation form. A score of at least 75% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.
Credit Fulfillment
- If you are requesting AMA credits or a certificate of participation, your certificate will be available for download
Course Viewing Requirements
This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox, and Safari browsers. Additionally, this site and its activities are best viewed using the latest operating system for your device.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, and Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Faculty for this educational activity are required to disclose when a therapy or procedure being discussed is off-label, unlabeled, experimental or investigational, and to note any limitations of the data presented (eg, preliminary findings, ongoing research, or expert opinion).
Some faculty may discuss uses of pharmaceutical agents or devices that are not included in U.S. Food and Drug Administration–approved labeling. These discussions are provided solely for educational purposes and should not be construed as a recommendation for any particular use. Learners are encouraged to review full prescribing information for products discussed.
Disclaimer
This activity is intended for health care professionals for educational purposes only. The content reflects information available at the time of development and may not represent the most current evidence, regulatory status, or prescribing information. Participants should consult current package inserts, clinical guidelines, and institutional policies before prescribing medications or making clinical decisions.
This activity has been planned and implemented in compliance with applicable accreditation standards to ensure that content is fair, balanced, evidence-based, and free of commercial bias.
Contact Information
If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or [email protected].